ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

ClinicalTrials.gov ID: NCT00435227

Public ClinicalTrials.gov record NCT00435227. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Single Intramuscular Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Outpatient Treatment of Children With RSV Illness

Study identification

NCT ID
NCT00435227
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
MedImmune LLC
Industry
Enrollment
12 participants

Conditions and interventions

Interventions

  • Motavizumab Biological
  • Placebo Other

Biological · Other

Eligibility (public fields only)

Age range
0 Months to 12 Months
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 19, 2007
Primary completion
May 30, 2008
Completion
May 30, 2008
Last update posted
Aug 16, 2021

2007 – 2008

United States locations

U.S. sites
31
U.S. states
18
U.S. cities
27
Facility City State ZIP Site status
Research Site Tucson Arizona
Research Site Jonesboro Arkansas 72401
Research Site Jonesboro Arkansas
Research Site Little Rock Arkansas 72202
Research Site Little Rock Arkansas
Research Site Orange California 92868
Research Site San Diego California 92103
Research Site Miami Florida
Research Site Tampa Florida 33606
Research Site Atlanta Georgia 30342
Research Site Augusta Georgia 30912
Research Site Chicago Illinois
Research Site Baltimore Maryland
Research Site Boston Massachusetts 02111
Research Site Detroit Michigan 48201
Research Site Las Vegas Nevada 89107
Research Site Paterson New Jersey 07503
Research Site Brooklyn New York 11203-2098
Research Site Buffalo New York 14222-2099
Research Site The Bronx New York
Research Site Youngstown Ohio 44051
Research Site Oklahoma City Oklahoma 73104
Research Site Nashville Tennessee 37232-2581
Research Site Dallas Texas 75230
Research Site Dallas Texas 75390
Research Site Houston Texas 77030
Research Site Richmond Virginia 23298
West Virginia University Pediactric Center Charleston West Virginia 25302
Research Site Charleston West Virginia 72205
Research Site Huntington West Virginia 25701-3655
Research Site Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00435227, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 16, 2021 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00435227 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →